Clinical trials: Clostridium Difficile
Clostridium Difficile
Fecal Transplant for Relapsing C. Difficile Infection
There has been an alarming increase in the incidence and severity of Clostridium difficile infection (CDI) in North America over the past decade.
- Trial name
- NCT01703494
- Testing
- Fecal Microbiota Transplantation
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Colleen Kelly
Recurrent Clostridium Difficile Infection, Laboratory Confirmed Clostridium Difficile Infection
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
Recurrent CDI is a growing problem with few treatment options that provide lasting effect. Fecal transplantation has been shown in several case series to be successful in controlling recurrent CDI.
- Trial name
- NCT01226992
- Testing
- Vancomycin, Fecal Transplant
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Antibiotic Associated Diarrhea, Clostridium Difficile Associated Diarrhea
Probiotics in Hospitalized Patients Study
The purpose of this study is to compare the effect of enhanced probiotic (EP, Live Rx) versus placebo (PL) on the incidence of Clostridium difficile associated diarrhea (CDAD) or antibiotic associated diarrhea (AAD) in…
- Trial name
- NCT01596153
- Testing
- Go Live
- Volunteers
- healthy volunteers welcome
- Sponsor
- South Shore Hospital
Clostridium Difficile Infection
An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84
An open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, A new vaccine against Clostridium Difficile (C. difficile), In healthy subjects
- Trial name
- NCT01296386
- Testing
- IC84
- Where
- 3 sites in Austria, Hungary
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Healthy, Clostridium Difficile Infection
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of…
- Trial name
- NCT01822977
- Testing
- omeprazole
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Development of Clostridium Difficile Associated Diarrhea
Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics
We have designed this study to measure the effect of normal flora supplementation, using available probiotics, on the incidence of Clostridium difficile-associated diarrhea in a population of general inpatients who are receiving…
- Trial name
- NCT01873872
- Testing
- Theralac probiotic, Culturelle probiotic
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- St. Vincent's East, Birmingham, Alabama
Clostridium Difficile Associated Disease
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
This is a first-in-human study (phase 1) of a 3-dose vaccination regimen with one of three dose levels of C difficile vaccine with or without adjuvant in healthy adults aged 50 to 85 years.
- Trial name
- NCT01706367
- Testing
- C. difficile vaccine, C. difficile vaccine +adjuvant
- Where
- 4 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
This study was developed in response to the July, 2013 FDA draft guidance regarding FMT for CDI. The weight of the evidence in the literature suggests that FMT is the most effective treatment for ambulatory outpatients affected…
- Trial name
- NCT01973465
- Testing
- Stool
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System
Clostridium Difficile Infection, Clostridium Difficile Diarrhea
Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity
This Phase I, randomized, placebo-controlled, double-blinded, dose ranging study to assess the safety, tolerability, and immunogenicity of 2 dose levels of C. difficile vaccine.
- Trial name
- NCT00772954
- Testing
- Vaccine diluent buffer, Clostridium difficile toxoid vaccine (50 μg), Clostridium difficile toxoid vaccine (100 μg)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Antibiotic-Associated Diarrhea, Clostridium Difficile-Associated Diarrhea
Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
The purpose of this study is to evaluate the efficacy and safety of Bio-K+ CL-1285 in the prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridum difficile-Associated Diarrhea (CDAD) in hospitalized patients exposed to…
- Trial name
- NCT00958308
- Testing
- BIO-K+ CL-1285®
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.